Back

Prevalence and implications of cardiomyopathy-associated genetic variants in early-onset atrial fibrillation

2 September 2024 (13:55 - 14:05)
Organised by: Logo
Congress Presentation Part of: The interplay between atrial fibrillation and heart failure: implications for clinicians Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mx Leo Wijdeveld

Amsterdam (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Incidence of atrial fibrillation detected by an insertable cardiac monitor in a large real-world cohort of heart failure patients with reduced and preserved ejection fraction
Mr S. Sarkar (Moundsview, US)
Abstract Slides Video
Presentation thumbnail
Long-term risk of heart failure and postoperative atrial fibrillation following noncardiac surgery: not so different from non-surgical atrial fibrillation
Ms M. Karacan (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Heart failure risk assessment using biomarkers in patients with atrial fibrillation: analysis of 32,041 patients from the COMBINE-AF study
Doctor P. Haller (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Prognostic implication of right ventricular - pulmonary arterial coupling in patients with non-valvular atrial fibrillation
Assistant Professor D. Kim (Incheon, KR)
Abstract Slides Video
Presentation thumbnail
Atrial Fibrillation (AF) detected by repeat handheld ECG screening and the risk of heart failure hospitalization
Doctor W. Sun (Shatin, HK)
Abstract Slides Video

Access the full session

Session thumbnail
The interplay between atrial fibrillation and heart failure: implications for clinicians
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 13:55 CET
You may be interested in
thumbnail
Congress Presentation
Early-onset atrial fibrillation is a risk marker for cardiomyopathy: genetic insights from the UK Biobank
thumbnail
Congress Presentation
Markers of atrial myopathy in the UK Biobank: prevalence, consequences, and risk stratification
thumbnail
Congress Presentation
Exome sequencing in over 63,000 patients in TIMI trials uncovers pathogenic cardiomyopathy variant carriers with high risk for heart failure and cardiovascular death

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources